cabazitaxel liposome (XZ126) / Lunan Pharma, Shanghai Pharmaceutical Group (Benxi) Northern Pharma - LARVOL DELTA

Disulfide-Crosslinked mPEG-PLA-(LA)4 Nanomicelles for Taxane Delivery in Breast Cancer Therapy. (PubMed, Molecules) - "The results demonstrated that the injectable paclitaxel, docetaxel, and cabazitaxel micelles exhibited significant inhibitory effects on the MCF-7 xenograft tumors. These findings suggest that mPEG-PLA-(LA)4 DS nanomicelles may serve as a structurally defined and versatile carrier platform for hydrophobic taxane delivery."

Journal • Breast Cancer • Oncology • Solid Tumor

Deciphering Apolipoprotein A4 in the Protein Corona of Ligand-Modified Liposomes for Tumor Targeting and Penetration. (PubMed, ACS Nano) - "Further studies revealed that the ligand modifications in liposomes could modulate the composition of their protein corona, particularly the level of Apolipoprotein A4 (ApoA4), which, in turn, influenced tumor targeting and intratumor distribution, ultimately affecting the therapeutic outcome of tumor inhibition and survival prolongation. This research provided a distinct correlation between ligand modification of liposomes and their in vivo biological performances, offering key insights for designing effective active-targeting nanomedicines."

Journal • Breast Cancer • Oncology • Solid Tumor

Case Report: Deep and durable PSA response to same-agent enzalutamide rechallenge in metastatic castration-resistant prostate cancer without chemotherapy. (PubMed, Front Oncol) - "Cabazitaxel is preferred after prior docetaxel and one ARSI...Following biochemical progression on enzalutamide in early 2025, which was accompanied by imaging findings suggestive of a new T12 lesion, and after a brief bicalutamide interval, enzalutamide was rechallenged under a time-limited, PCWG3-aligned protocol with predefined stop rules...This case suggests that in a preference-constrained, chemotherapy-naïve patient, same-agent enzalutamide rechallenge can yield a clinically meaningful PSA response. The observation raises the hypothesis that ARSI resistance may be reversible in a subset of patients, warranting prospective evaluation of biomarker-guided rechallenge strategies to optimize patient selection and minimize opportunity cost."

Journal • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hormone Sensitive Prostate Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor